Drug
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Recombinant oncolytic herpes simplex virus type Ⅰ (R130) is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph early_phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
3(100.0%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 13 (100.0%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingearly_phase_1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
NCT06171282
recruitingearly_phase_1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
NCT05851456
recruitingearly_phase_1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
NCT05812677
Clinical Trials (3)
Showing 3 of 3 trials
NCT06171282Early Phase 1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
NCT05851456Early Phase 1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
NCT05812677Early Phase 1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3